Putting Rare Disease Organization in the Business of Drug Development

RARECast

Rare disease patient organizations are increasingly driving the discovery and development of therapies to treat the conditions on which they are focused. Organizations are seeking ways to accelerate these programs and advance them to the point where a biopharmaceutical partner might be willing to take them over. DevineBio was created to partner with patient organizations and provide them with the capability to discover and develop therapies and advance them to the clinic. We spoke to Chris Hopkins, CEO of DevineBio, about how the company works with patient organizations, how far it will advance programs, and its exit strategy.